Background/Objectives: No prospective study on the long-term effects of gastric resection on gastrointestinal hormonal changes in patients with normal body weight has been reported. The aim of this study was to evaluate the 1-year effect of subtotal gastrectomy on ghrelin and peptide YY (PYY) 3À36 levels. Subjects/Methods: Eighteen patients with early gastric cancer underwent subtotal gastrectomy with Billroth I reconstruction. We assessed appetite, food intake, body composition, and ghrelin and PYY 3-36 levels preoperatively and 1 year after surgery. Results: There were no significant difference in the preoperative daily food intake and 1 year after subtotal gastrectomy. Weight loss occurred in all study subjects; 11.7% (n ¼ 2), 55.5% (n ¼ 10) and 33.3% (n ¼ 6) of the patients lost o5%, 5-10% and 410% of their preoperative body weight, respectively. Body mass index, waist circumference and body fat significantly decreased 1 year after subtotal gastrectomy. There were no significant differences in the appetite visual analogue scale preoperatively and 1 year after subtotal gastrectomy. The plasma ghrelin concentration decreased significantly (P ¼ 0.006), whereas PYY 3À36 did not show a significant change 1 year after subtotal gastrectomy. Conclusions: Ghrelin levels and body fat decreased significantly, whereas PYY 3À36 levels as well as appetite and food intake did not change significantly 1 year after subtotal gastrectomy with normal body weight. These findings suggest that decreased ghrelin might contribute directly to reduced body fat.
Introduction
Ghrelin, a 28-amino-acid peptide with an n-octanoylation indispensable for its biological activity, is produced mainly by the stomach and contributes to 70% of the circulating concentration of ghrelin (Jeon et al., 2004) . Ghrelin has been shown to induce not only growth hormone release from the pituitary gland, but also to increase appetite and stimulate weight gain (Wren et al., 2000) Peptide YY (PYY) 1À36 is released into the circulation from L-type endocrine cells of the distal intestine (Adrian et al., 1985) . After release, biologically active PYY 3-36 is formed by cleavage of the N-terminal residues by dipeptidyl peptidase IV (le Roux and Bloom, 2005) . In addition to various suppressive functions in the gastrointestinal tract, PYY 3-36 induces physiologic postprandial satiety by counterregulation of ghrelin release through the Y2-receptor in the hypothalamus (McGowan and Bloom, 2004) .
Gastrointestinal hormones, such as ghrelin and PYY 3-36 , have been reported to have important roles in determining food intake and body weight (Wren et al., 2000; McGowan and Bloom, 2004) . However, little is known about the longterm effects of gastric resection on these peptides. According to previous studies, removal of the entire stomach in humans reduces the plasma ghrelin concentration by 65%, 1-8 years after surgery (Ariyasu, 2001) ; sleeve gastrectomy also reduces the plasma ghrelin level and increases PYY in morbidly obese patients (Karamanakos et al., 2008) . Of note, these findings reflect a retrospective cohort study in which patients who had undergone gastric resection and healthy controls or patients undergoing bariatric surgery for weight reduction in morbidly obese patients were compared. No prospective studies of the long-term effects of gastric resection on gastrointestinal hormonal changes in patients with normal body weight have been reported. Therefore, we prospectively evaluated the changes in ghrelin and PYY 3-36 concentrations preoperatively and 1 year after gastric resection in patients with early gastric cancer who underwent a subtotal gastrectomy.
Methods
Patients with early gastric cancer who underwent a subtotal gastrectomy at the Pusan National University Hospital between January 2004 and December 2005 comprised the study subjects. Early gastric cancer is defined by the Japanese Research Society for Gastric Cancer as cancer in which the tumor cells invade only the mucosal and submucosal layers (Japanese Gastric Cancer Association, 1998).
Subtotal gastrectomy was defined as the surgical removal of the distal two-thirds of the stomach; the restoration method of digestive continuity was a Billroth I gastroduodenostomy. Patients with endocrine diseases, such as diabetes mellitus, thyroid disease and pituitary disease, were excluded from this study, as were patients with tumors 42 cm in diameter. Written informed consent was obtained from each subject before enrollment in this study. The study was approved by the institutional review board of the Medical Research Institute of Pusan National University and was performed in accordance with the Declaration of Helsinki Principles.
All study subjects were evaluated for food intake, body composition, appetite and gastrointestinal hormones (ghrelin and PYY 3À36 ) preoperatively and 1 year after surgery. The average follow-up period was 12.1 months (s.d., 2.3 months). Of 21 patients, 3 (14.3%) were lost to follow-up during the study period. Eighteen patients with gastric cancer were studied (Table 1) . However, no significant difference was found between inclusion and exclusion patients regarding their basal characteristics.
Daily energy and nutrient intake were assessed by a semiquantitative food frequency questionnaire. Subjects were asked to report the average frequency of consumption and portion size of each food on a weekly basis during the previous 3 months by an experienced dietitian (Lee et al., 2006) . Subjects also were asked to maintain physical activity levels throughout the study period. The height, weight and waist circumference were measured with the subjects wearing a light gown, but no shoes. Body composition was measured using dual energy X-ray absorptiometry (Lunar Prodigy; GE Medical Systems, Waukesha, WI, USA), which is a sensitive test to quantify changes in lean and fat mass in vivo (Going, 1993) and assessing regional fat distribution (Taylor et al., 1998) . All of the scans were analyzed with Lunar software, package l.35. The coefficients of variation were 2.6% for fat mass, 2.5% for total body fat percentage, o3% for regional fat measures and 0.88% for lean mass.
Appetite was assessed using a horizontal visual analogue scale (VAS), 100 mm in length, with words anchored at each end, expressing the most positive (100 mm) and the most negative rating (0 mm) (Flint et al., 2000) .
Blood samples were obtained at 0800 hours preprandially after an overnight fast for the determination of plasma ghrelin and PYY 3À36 . Blood samples were drawn into chilled tubes containing Na 2 EDTA (1 mg/ml) and aprotinin (500 U/ml). Plasma was immediately separated by centrifugation at 41C and stored at À701C until assayed. Plasma total ghrelin was measured with a commercially available radioimmunoassay kit (Phoenix Pharmaceuticals Inc., Belmont, CA, USA), using 125 I-labeled bioactive ghrelin as a tracer molecule and a polyclonal rabbit antibody against fulllength octanoylated human ghrelin, which measures total circulating ghrelin levels. The lower and upper limits of detection were 10 and 1280 pg/ml, respectively. The mean intra-and inter-assay coefficients of variation were 4.8 and 3.5%, respectively. The radioimmunoassay did not show any cross-reaction with human leptin. Plasma PYY 3À36 was measured with a commercially available kit (Linco Research Inc., St. Charles, MO, USA). The antibody, raised in guinea pigs, has 100% cross-reactivity with human PYY 3À36 , but no cross-reactivity with human pancreatic polypeptide, NPY, and unrelated peptides, such as leptin and ghrelin. 125 I-PYY was used as a label; the labeled peptide was purified by HPLC (specific activity, 302 kCi/kg). The lowest level of PYY detected by this assay was 10 pg/ml using a 100 ml plasma sample. Intra-and inter-assay coefficients of variation were o9%. All procedures were performed at 4 1C.
The data are expressed as the mean ± s.d. A paired t-test was used to determine the statistical significance of the differences in calorie intake, appetite, body composition, ghrelin and PYY 3À36 levels preoperatively and 1 year after 
Results

Demographic data
The 18 study subjects had a mean age of 56 years, with a range of 28-74 years. The mean body mass index was 23.8 kg/m 2 , with a range of 18.9-28.2 kg/m 2 . The majority of the subjects (83.3%) were men ( Table 1) .
Evaluation of food intake
The average daily dietary intake is shown in Table 2 . No significant differences existed in the daily total calorie, protein, fat and carbohydrate intake preoperatively and 1 year after subtotal gastrectomy ( Table 2) .
Evaluation of body composition
Weight loss occurred in all study subjects after subtotal gastrectomy. Of the study subjects, 11.7% (n ¼ 2), 55.5% (n ¼ 10) and 33.3% (n ¼ 6) lost o5, 5-10 and 410% of their preoperative body weight, respectively, 1 year after surgery. The body mass index, waist circumference and body fat percentage, as measured by dual energy X-ray absorptiometry, decreased to 90.4 ± 5.0, 89.7 ± 5.7 and 76.2 ± 9.7% after 1 year of subtotal gastrectomy, but fat-free mass did not result in a statistically significant change after surgery ( Table 2) .
Evaluation of appetite
There were no significant differences in the VAS appetite ratings preoperatively and 1 year after subtotal gastrectomy (Table 2 and Figure 1 ).
Evaluation of ghrelin and PYY 3À36 levels
The total plasma level reached a nadir of 42.8% at 1 h after gastric resection and gradually increased to 85.8% by postoperative day 7. However, finally the total plasma ghrelin level decreased significantly (from 113.0±46.1 to 65.2 ± 26.6 pg/ml; P ¼ 0.006) 1 year after subtotal gastrectomy (Figure 2) . The PYY 3À36 concentration decreased to 78.9% at postoperative day 7, but did not result in a statistically significant change within 1 year after subtotal gastrectomy (Figure 2) .
Discussion
This is the first prospective study, to our knowledge, to evaluate long-term effects of gastric resection on gastrointestinal hormonal changes in patients with 'normal body weight'. Ghrelin is primarily produced in the stomach and transmits a peripheral appetite-stimulatory signal to the brain, thus inducing food intake (Wren et al., 2000;  
Jeon et al., 2004
). The concentration of ghrelin increases in the fasting state or before meals and stimulates appetite by activation of neurons in the arcuate nucleus of the hypothalamus, whereas circulating concentrations decrease rapidly after the meal in response to food intake. The obese individuals have higher plasma ghrelin concentrations and lean individuals have lower plasma ghrelin concentrations than healthy controls. PYY 3À36 is primarily secreted from the distal intestinal tract and induces postprandial satiety. The plasma PYY 3À36 concentration remains low preprandially, but increases after food ingestion; PYY 3À36 stimulates satiety and reduces hunger through hypothalamic Y2 receptors (Adrian et al., 1985; McGowan and Bloom, 2004) . Plasma PYY 3À36 concentrations are lower in obese people compared to normal weight controls and are inversely proportional to the body mass index. These findings suggest that ghrelin and PYY 3À36 have important roles in appetite control, as well as energy homeostasis, in the regulation of body weight. Gastric resection is the surgical removal of part or all of the stomach, and is usually performed in the treatment of gastric cancer or intractable peptic ulcers. Patients who undergo gastric resection commonly lose body weight. A reduced caloric intake and malabsorption are considered the most important factors contributing to weight loss after gastric resection (Braga et al., 1988) . Because ghrelin is produced mainly by the stomach, weight loss after gastric resection may be accompanied by impaired ghrelin production. Thus, gastrointestinal peptide changes may also be involved in weight loss after gastric resection. However, no prospective studies of the long-term effects of gastric resection on gastrointestinal hormonal changes in patients with normal body weight have been reported.
In this study, there were no significant differences in the daily intake of total calorie, protein, fat and carbohydrate preoperatively and 1 year after subtotal gastrectomy (Table 2) . One could expect that after total gastrectomy, loss of the gastric reservoir reduces calorie intake, which is a major cause of weight loss (Liedman et al., 1996) . However, after subtotal gastrectomy, no significant difference in food intake was found preoperatively and 1 year after surgery. This might be due to partial restoration of the reservoir function of the remnant stomach and the increased frequency of food intake.
It has been reported that weight loss usually occurs early, especially within the first 6 months after surgery, although data on changes in body composition after subtotal gastrectomy are limited (Liedman et al., 1997) . Our study showed that body weight, body mass index, waist circumference and body fat percentage were decreased 1 year after subtotal gastrectomy, whereas fat-free mass did not change (Table 2 ). These findings suggest that reduced body fat is the most important factor contributing to weight loss after gastrectomy. The reduction of body fat results in weight loss and reduced body mass index after subtotal gastrectomy. In a study about changes in body composition after gastrectomy, it has been reported that approximately 90% of weight loss is caused by reduced body fat (Liedman et al., 1997) . However, the reason why the decrease in body fat is most sensitive among compartments of body composition after gastrectomy is unknown.
The stomach is the principal site of ghrelin production, which contributes 70% of the ghrelin levels in humans (Jeon et al., 2004) . Therefore, we hypothesized that ghrelin levels would decrease after gastrectomy, which results in loss of appetite and body weight. However, contrary to our expectations, no significant differences in VAS appetite ratings occurred before and 1 year after subtotal gastrectomy (Figure 1 ). The underlying mechanism is unknown, but appetite and satiety controls are mediated by a complicated interplay of neuroendocrine signaling pathways involving a great variety of peptide hormones and neuropeptides, including ghrelin and PYY 3À36 (Romijn et al., 2008) Although appetite-stimulating plasma ghrelin concentrations decrease after gastrectomy, appetite would not have been changed due to compensation of other hormones involved in the control of appetite and food intake. Positive emotions to overcome the cancer in patients with gastric cancer who underwent gastrectomy may positively influence the subjective VAS appetite ratings 1 year after surgery (Boström et al., 2003) . We reported that compensatory ghrelin production occurred in the remnant stomach after the surgical removal of part of the stomach as well as other tissues or organs such as the bowel, pancreas, kidney and placenta in postoperative day 7 (Jeon et al., 2004) . In this study, however, finally plasma ghrelin concentrations were significantly decreased 1 year after subtotal gastrectomy. Plasma PYY 3À36 concentrations also decreased gradually according to the changes in the plasma concentration of ghrelin, but did not change 1 year after subtotal gastrectomy. Therefore, it seems unlikely that compensatory ghrelin production remains so in the long-term, although it can occur transiently. Ghrelin is known to enhance appetite and increase food intake in the short term and maintain body fat in the long term (Dornonville de la Cour et al., 2005) . In this study, appetite did not change 1 year after subtotal gastrectomy, but body fat decreased significantly compared to before surgery, which is considered to be closely related to reduced ghrelin concentrations. These observations also indicate that ghrelin may act directly on fat metabolism by a peripheral mechanism rather than through a central mechanism. Ghrelin is known to maintain a positive energy balance by suppression of fat utilization without a change in energy expenditure (Tschöp et al., 2000) . Thus, low levels of circulating ghrelin in subtotal gastrectomized patients appear to contribute to a loss of body fat and body weight. The mechanism underlying fat loss by reduced ghrelin levels is unknown. Recently, one human study showed a significant positive correlation between the total plasma ghrelin level and the whole-body respiratory quotient (Doucet et al., 2004) . The respiratory quotient has been used as an indicator of the glucose-to-fat oxidation rate, reflecting macronutrient oxidation. Ghrelin increases the respiratory quotient in mice, suggesting an increased use of carbohydrates and decreased use of fat as an energy source (Frayn, 1983) . These results suggest that the effect of ghrelin on body composition may be mediated by changes in fuel preference rather than food intake. Although the reduced circulating ghrelin concentration may contribute to body fat loss, future studies should further clarify the mechanisms of action of ghrelin in fat metabolism.
Our study has some limitations, including the relatively small size of the study sample and the fact that no attempt was made to measure acylated and de-acylated ghrelin. The other limitations are the lack of data about physical activity levels, which may also affect changes in body weight and ghrelin, although we asked the subjects to maintain physical activity levels throughout the study period. Considering these limitations, further research is needed to reconfirm these findings.
In summary, we have shown that the plasma concentration of ghrelin is decreased 1 year after subtotal gastrectomy in early gastric cancer patients with normal body weight. However, the plasma concentration of PYY 3À36 , as well as appetite and food intake, did not show a significant change 1 year after subtotal gastrectomy. These findings suggest that decreased ghrelin might contribute directly to reduced body fat.
